...
首页> 外文期刊>Modern Pathology >p27kip1 Expression Distinguishes Papillary Hyperplasia in Graves|[rsquo]| Disease from Papillary Thyroid Carcinoma
【24h】

p27kip1 Expression Distinguishes Papillary Hyperplasia in Graves|[rsquo]| Disease from Papillary Thyroid Carcinoma

机译:p27kip1表达可区分Graves中的乳头状增生| [rsquo] |乳头状甲状腺癌疾病

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In most cases, the histopathologic and cytologic distinction between Graves' disease and papillary thyroid carcinoma is relatively easy, but on occasion Graves' disease may simulate a thyroid papillary carcinoma. For example, papillary fronds with fibrovascular cores may be present in both Graves' disease and papillary carcinoma. p27kip1 (p27) is a cyclin-dependent kinase inhibitory protein that has been shown to be an independent prognostic factor in a variety of human tumors. Our previous studies of p27 expression in hyperplastic and neoplastic endocrine lesions showed that the level of p27 was quite different in these two conditions. To determine if this distinction could also be made between Graves' disease and papillary carcinoma, we analyzed expression of p27 and other cell cycle proteins in a series of cases of Graves' disease with papillary hyperplasia and a series of papillary thyroid carcinomas. Formalin-fixed paraffin-embedded tissues from 61 randomly selected patients with thyroid disease, including 29 cases of Graves' disease with papillary architectural features and 32 cases of papillary carcinoma, were analyzed for expression of p27, Ki-67, and DNA topoisomerase II (topo II ) by immunostaining. The distribution of immunoreactivity was analyzed by quantifying the percentage of positive nuclei that was expressed as the labeling index (LI) plus or minus the standard error of the mean. The papillary hyperplasia of Graves' disease had a p27 LI of 68.2 3.1 (range, 24 to 88), whereas papillary carcinomas had a LI of 25.6 2.5 (range, 12 to 70) (P < .0001). No significant differences in Ki-67 or topo II expression were identified between papillary hyperplasia in Graves' disease and papillary carcinoma. These results indicate that p27 protein expression is significantly higher in papillary hyperplasia of Graves' disease compared to papillary carcinoma, which may be diagnostically useful in difficult cases.
机译:在大多数情况下,格雷夫斯病和甲状腺乳头状癌之间的组织病理学和细胞学区别相对容易,但有时格雷夫斯病可能会模拟甲状腺乳头状癌。例如,在格雷夫斯氏病和乳头状癌中都可能存在具有纤维血管核心的乳头状叶状体。 p27kip1(p27)是一种细胞周期蛋白依赖性激酶抑制蛋白,已被证明是多种人类肿瘤中的独立预后因素。我们先前对增生性和肿瘤性内分泌病变中p27表达的研究表明,在这两种情况下,p27的水平差异很大。为了确定在Graves病和乳头状癌之间是否也可以进行区分,我们分析了一系列Graves病伴乳头状增生和一系列甲状腺乳头状癌的病例中p27和其他细胞周期蛋白的表达。分析了61例甲状腺疾病患者的福尔马林固定石蜡包埋组织,包括29例具有乳头结构特征的Graves病和32例乳头状癌,分析了p27,Ki-67和DNA拓扑异构酶II的表达( topo II),通过免疫染色。通过量化阳性细胞核的百分比(表示为标记指数(LI)加上或减去平均值的标准误)来分析免疫反应性的分布。 Graves病的乳头状增生的p27 LI为68.2 3.1(范围为24至88),而乳头状癌的LI值为25.6 2.5(范围为12至70)(P <.0001)。 Graves病的乳头状增生与乳头状癌之间的Ki-67或topo II表达没有显着差异。这些结果表明,与乳头状癌相比,在Graves病的乳头状增生中p27蛋白的表达明显更高,这在困难情况下可能具有诊断意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号